These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31292842)

  • 1. A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection.
    Miyasaka A; Yoshida Y; Suzuki A; Ueda H; Morino Y; Takikawa Y
    Clin J Gastroenterol; 2020 Feb; 13(1):90-96. PubMed ID: 31292842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
    Knop V; Hoppe D; Welzel T; Vermehren J; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Zeuzem S; Welker MW
    J Viral Hepat; 2016 Dec; 23(12):994-1002. PubMed ID: 27500382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.
    Persico M; Rosato V; Aglitti A; Precone D; Corrado M; De Luna A; Morisco F; Camera S; Federico A; Dallio M; Claar E; Caporaso N; Masarone M
    Antivir Ther; 2018; 23(2):129-138. PubMed ID: 28799522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
    Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
    HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
    Maki H; Kubota K; Hatano M; Minatsuki S; Amiya E; Yoshizaki A; Asano Y; Morita H; Sato S; Komuro I
    Int Heart J; 2020; 61(2):413-418. PubMed ID: 32224603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?
    Yukawa Y; Tamori A; Iio E; Ogawa S; Yoshida K; Uchida-Kobayashi S; Enomoto M; Tanaka Y; Kawada N
    Clin J Gastroenterol; 2019 Dec; 12(6):598-602. PubMed ID: 31165460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis.
    Abadía M; Montes ML; Ponce D; Froilán C; Romero M; Poza J; Hernández T; Fernández-Martos R; Olveira A;
    World J Gastroenterol; 2019 Jun; 25(21):2665-2674. PubMed ID: 31210717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity.
    Nguyen HH; Khathlan A; Fritzler MJ; Swain MG
    BMC Gastroenterol; 2018 Jun; 18(1):97. PubMed ID: 29940867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
    Luo Q; Jin Q; Zhao Z; Zhao Q; Yu X; Yan L; Zhang Y; Xiong C; Liu Z
    BMC Pulm Med; 2019 Dec; 19(1):257. PubMed ID: 31856792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
    Mandorfer M; Kozbial K; Freissmuth C; Schwabl P; Stättermayer AF; Reiberger T; Beinhardt S; Schwarzer R; Trauner M; Ferlitsch A; Hofer H; Peck-Radosavljevic M; Ferenci P
    Aliment Pharmacol Ther; 2015 Sep; 42(6):707-18. PubMed ID: 26179884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    Joye R; Lador F; Aggoun Y; Farhat N; Wacker J; Wildhaber BE; Vallée JP; Hachulla AL; McLin VA; Beghetti M
    J Hepatol; 2021 Mar; 74(3):742-747. PubMed ID: 33276028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals.
    Giannini EG; Crespi M; Demarzo M; Bodini G; Furnari M; Marabotto E; Torre F; Zentilin P; Savarino V
    Eur J Clin Invest; 2019 Mar; 49(3):e13056. PubMed ID: 30474209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.